Message #32 From:
NewsBot Date: October 4, 2006 05:30:00 AM
EVSC News Endovasc Announces Completion of LC/MS Assay by ABC Laboratories for Phase III Trial of Liprostin
HOUSTON--(BUSINESS WIRE)--ENDOVASC INC. (OTCBB:EVSC),
today announced that Analytical Bio-Chemical Laboratories, Inc. (ABC)
has developed a highly sensitive High Performance Liquid
Chromatography/Mass spectrophotometric assay (LC/MS) to detect
prostaglandin E-1 (PGE-1) in the serum of patients treated with
Liprostin.
Additionally, ABC has determined a method to separate free PGE-1 from
encapsulated PGE-1, allowing direct measurement of the release rate of
the drug from the liposome during and post-treatment of Liprostin in the
patient. These methods will be used to conduct pharmacokinetic studies
during Endovasc’s Phase III trials.
Diane Dottavio, Ph.D., Endovasc's Chairman and Chief Executive Officer,
commented, “ABC has provided us with a very
important assay which will help us to determine the metabolic clearance
rate of our drug, and perhaps answer questions regarding its mechanism
of action and apparent ‘long-acting’
effect seen in our Phase II results.”
Endovasc's Liprostin is a liposome-encapsulated form of prostaglandin
E-1 (PGE-1) which is known to be a potent vasodilator and platelet
inhibitor as well as an anti-inflammatory and anti-thrombotic agent. In
February 2006, Endovasc submitted its protocol for the phase IIIa
clinical trial of Liprostin for treatment of intermittent claudication,
a symptom of Peripheral Arterial Disease, to the FDA. Intermittent
claudication causes a cramping sensation in the legs that is present
during exercise or walking and occurs as a result of decreased blood and
oxygen supply. If left untreated, clots may form and lead to leg ulcers,
gangrene and ultimately amputation.
About Analytical Bio-Chemistry Laboratories, Inc.
Analytical Bio-Chemistry Laboratories, Inc. based in Columbia, MO, is a
contract research and development company that provides analytical and
biological services in support of U.S. and global product registrations
for the pharmaceutical industry. Established in 1968, the company
provides scientific consulting, custom synthesis, in-vitro/in-vivo
services, pharmacokinetics, bio-analysis, and a full spectrum of cGMP
analytical services. Through partnerships and industry alliances, ABC
Labs provides unparalleled service and depth of experience that helps
accelerate IND and NDA submissions and minimize time to market.
Endovasc, Inc is focused on developing and commercializing drug
candidates in the areas of cardiovascular and metabolic medicine.
Endovasc is organized as a business development company, operating
through the following subsidiaries: Liprostin Inc., which holds the
intellectual property for a liposomal based treatment to increase
circulation and reduce leg pain in patients suffering from vascular
disease; Prostent, Inc., which is developing a stent coating technology;
and Nutraceutical Development Corporation. For more information about
Endovasc, please visit www.endovasc.com.
Safe Harbor:
This press release contains forward-looking statements within the
meaning of section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. With the exception of historical
information contained herein, the matters discussed in this press
release involve risk and uncertainties. Actual results could differ
materially from those expressed in any forward-looking statement.
